An announcement from Neurogene ( (NGNE) ) is now available.
Neurogene Inc. has reported its first quarter 2025 financial results and provided updates on its NGN-401 gene therapy for Rett syndrome. The company plans to update on its registrational trial in the first half of 2025 and expects to share interim clinical data in the second half of the year. With a cash runway extending into the second half of 2027, Neurogene is well-positioned to complete the enrollment of future trials and further develop its gene therapy pipeline. The company also announced a peer-reviewed publication demonstrating the efficacy of its EXACT™ transgene regulation technology, which supports the development of NGN-401.
Spark’s Take on NGNE Stock
According to Spark, TipRanks’ AI Analyst, NGNE is a Underperform.
Neurogene’s overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.
To see Spark’s full report on NGNE stock, click here.
More about Neurogene
Neurogene Inc. is a clinical-stage company focused on developing genetic medicines to treat rare neurological diseases. The company aims to improve the lives of patients and families affected by these conditions through innovative treatments that address the limitations of conventional gene therapy.
Average Trading Volume: 261,015
Technical Sentiment Signal: Sell
Current Market Cap: $197.7M
For a thorough assessment of NGNE stock, go to TipRanks’ Stock Analysis page.